Gatto Emilia M, Da Prat Gustavo, Etcheverry Jose Luis, Drelichman Guillermo, Cesarini Martin
Department of Neurology, Parkinson's Disease and Movement Disorders Section, Institute of Neuroscience of Buenos Aires (INEBA). Guardia Vieja 4435, Buenos Aires C1192AAW, Argentina.
Hospital de Niños Ricardo Gutiérrez, Gallo 1330, Buenos Aires C1425EFD, Argentina.
Brain Sci. 2019 Feb 1;9(2):30. doi: 10.3390/brainsci9020030.
In the last years, lysosomal storage diseases appear as a bridge of knowledge between rare genetic inborn metabolic disorders and neurodegenerative diseases such as Parkinson's disease (PD) or frontotemporal dementia. Epidemiological studies helped promote research in the field that continues to improve our understanding of the link between mutations in the glucocerebrosidase (GBA) gene and PD. We conducted a review of this link, highlighting the association in GBA mutation carriers and in Gaucher disease type 1 patients (GD type 1). A comprehensive review of the literature from January 2008 to December 2018 was undertaken. Relevance findings include: (1) There is a bidirectional interaction between GBA and α- synuclein in protein homeostasis regulatory pathways involving the clearance of aggregated proteins. (2) The link between GBA deficiency and PD appears not to be restricted to α⁻synuclein aggregates but also involves Parkin and PINK1 mutations. (3) Other factors help explain this association, including early and later endosomes and the lysosomal-associated membrane protein 2A (LAMP-2A) involved in the chaperone-mediated autophagy (CMA). (4) The best knowledge allows researchers to explore new therapeutic pathways alongside substrate reduction or enzyme replacement therapies.
在过去几年中,溶酶体贮积病成为罕见遗传性先天性代谢紊乱与神经退行性疾病(如帕金森病(PD)或额颞叶痴呆)之间的知识桥梁。流行病学研究推动了该领域的研究,不断增进我们对葡糖脑苷脂酶(GBA)基因突变与PD之间联系的理解。我们对这一联系进行了综述,重点阐述了GBA突变携带者和1型戈谢病(GD1型)患者中的关联。我们对2008年1月至2018年12月的文献进行了全面综述。相关研究结果包括:(1)在涉及聚集蛋白清除的蛋白质稳态调节途径中,GBA与α-突触核蛋白之间存在双向相互作用。(2)GBA缺乏与PD之间的联系似乎不仅限于α-突触核蛋白聚集体,还涉及帕金蛋白和PINK1突变。(3)其他因素有助于解释这种关联,包括早期和晚期内体以及参与伴侣介导自噬(CMA)的溶酶体相关膜蛋白2A(LAMP-2A)。(4)现有的最佳知识使研究人员能够在底物减少或酶替代疗法之外探索新的治疗途径。